Phase 1 single ascending dose pharmacokinetics study: parent/metabolite(S). Analytical services center for medications development. July 20, 2026 - january 19, 2028. Task order 02. DAP-ncap-00000009
Active Awarded Last action
- Contract number
- 75N98026F00002
- Awardee
-
Mriglobal UEI HKQHNFKNKL15
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $478,052
Award facts
- Opportunity
-
- 75N98026D00031TO02 Solicitation number
- Contract value 100% obligated
- $478,052.00 Current and potential, with all options
- Completion date 20% complete
- Current and potential, with all options
- Funding agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Kansas City, MO 64110, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Drug Abuse issued a delivery order to Mriglobal (doing business as Midwest Research Institute) on July 20, 2026, with a ceiling value of $478,052, under a cost-plus-fixed-fee pricing structure for a Phase 1 single ascending dose pharmacokinetics study of parent and metabolite compounds as part of the Analytical Services Center for Medications Development.
Place of performance is Kansas City, Missouri. The order extends through January 19, 2028. The delivery order calls against a parent indefinite delivery vehicle supporting analytical and pharmaceutical services to NIDA's research programs. Mriglobal is a large, unrestricted nonprofit research organization based in Kansas City that delivers clinical-grade pharmaceutical manufacturing, preclinical testing, diagnostic services, and biodefense research and development across federal health, defense, and homeland security missions.
Quick answers
Who was awarded contract 75N98026F00002?
75N98026F00002 was awarded to Mriglobal by Office of Logisitics and Acquisition Operations (National Institutes of Health) on July 20, 2026.
How much is contract 75N98026F00002 worth?
The government has obligated $478,052 on 75N98026F00002.
Which agency awarded contract 75N98026F00002?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026F00002, with funding from National Institute on Drug Abuse (National Institutes of Health).
Is contract 75N98026F00002 an order under another contract?
Yes. 75N98026F00002 is a delivery order under 75N98026D00031, an indefinite delivery contract.
Was contract 75N98026F00002 competed?
The extent of competition for 75N98026F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award